Skyline Ventures

Skyline Ventures is a Palo Alto-based life-sciences venture capital firm founded in 1997 by John G. Freund and Eric M. Gordon, both of whom came to venture capital from medical and healthcare operating backgrounds. A defining feature of the firm is that every investment professional holds either an MD or PhD, enabling deep scientific diligence on the product-focused healthcare companies Skyline backs. Investment focus is concentrated in US-based small-molecule and protein therapeutics, medical devices, diagnostics, and the platform technologies that underpin drug discovery and life-science research. The firm has raised approximately $800 million across multiple vehicles; its latest fund, Skyline V, holds $350 million in committed capital and was sized to back 15 to 18 portfolio companies. Skyline leads rounds and applies unusually explicit check-sizing discipline: the firm typically invests $15 million to $25 million of total capital per portfolio company across multiple rounds, with first cheques in the $10 million to $15 million range. Across roughly 46 unique portfolio companies and 102 total deals on record, the firm has generated 10 IPOs and 26 acquisitions. Landmark names include Intuitive Surgical, Sutro Biopharma (which listed on NASDAQ in September 2018), and Theravance Biopharma. John Freund continues to serve as Founder and Managing Partner, supported by a compact team of around seven investment professionals. Skyline's approach is to engage deeply with each company across multiple rounds rather than spreading capital broadly -- a philosophy that prioritizes scientific conviction over portfolio diversification. The firm currently manages Skyline V through its harvest cycle, with limited new deployment in recent years as it focuses on maximizing outcomes across existing holdings.